BACKGROUND: The association between initiation of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection and possible herpes simplex virus type2 (HSV-2) shedding and genital ulcer disease (GUD) has not been evaluated. METHODS:GUD and vaginal HSV-2 shedding were evaluated among women coinfected with HIV and HSV-2 (n = 440 for GUD and n = 96 for HSV-2 shedding) who began ART while enrolled in a placebo-controlled trial of HSV-2 suppression with acyclovir in Rakai, Uganda. Monthly vaginal swabs were tested for HSV-2 shedding, using a real-time quantitative polymerase chain reaction assay. Prevalence risk ratios (PRRs) of GUD were estimated using log binomial regression. Random effects logistic regression was used to estimate odds ratios (ORs) of HSV-2 shedding. RESULTS: Compared with pre-ART values, GUD prevalence increased significantly within the first 3 months after ART initiation (adjusted PRR, 1.94; 95% confidence interval [CI], 1.04-3.62) and returned to baseline after 6 months of ART (adjusted PRR, 0.80; 95% CI, .35-1.80). Detection of HSV-2 shedding was highest in the first 3 months after ART initiation (adjusted OR, 2.58; 95% CI, 1.48-4.49). HSV-2 shedding was significantly less common among women receiving acyclovir (adjusted OR, 0.13; 95% CI, .04-.41). CONCLUSIONS: The prevalence of HSV-2 shedding and GUD increased significantly after ART initiation, possibly because of immune reconstitution inflammatory syndrome. Acyclovir significantly reduced both GUD and HSV-2 shedding and should be considered to mitigate these effects following ART initiation.
RCT Entities:
BACKGROUND: The association between initiation of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection and possible herpes simplex virus type 2 (HSV-2) shedding and genital ulcer disease (GUD) has not been evaluated. METHODS: GUD and vaginal HSV-2 shedding were evaluated among women coinfected with HIV and HSV-2 (n = 440 for GUD and n = 96 for HSV-2 shedding) who began ART while enrolled in a placebo-controlled trial of HSV-2 suppression with acyclovir in Rakai, Uganda. Monthly vaginal swabs were tested for HSV-2 shedding, using a real-time quantitative polymerase chain reaction assay. Prevalence risk ratios (PRRs) of GUD were estimated using log binomial regression. Random effects logistic regression was used to estimate odds ratios (ORs) of HSV-2 shedding. RESULTS: Compared with pre-ART values, GUD prevalence increased significantly within the first 3 months after ART initiation (adjusted PRR, 1.94; 95% confidence interval [CI], 1.04-3.62) and returned to baseline after 6 months of ART (adjusted PRR, 0.80; 95% CI, .35-1.80). Detection of HSV-2 shedding was highest in the first 3 months after ART initiation (adjusted OR, 2.58; 95% CI, 1.48-4.49). HSV-2 shedding was significantly less common among women receiving acyclovir (adjusted OR, 0.13; 95% CI, .04-.41). CONCLUSIONS: The prevalence of HSV-2 shedding and GUD increased significantly after ART initiation, possibly because of immune reconstitution inflammatory syndrome. Acyclovir significantly reduced both GUD and HSV-2 shedding and should be considered to mitigate these effects following ART initiation.
Entities:
Keywords:
Uganda; acyclovir; herpes simplex virus type 2 (HSV-2); human immunodeficiency virus (HIV); immune reconstitution inflammatory syndrome (IRIS); reactivation
Authors: Niloufar Ameli; Peter Bacchetti; Rhoda Ashley Morrow; Nancy A Hessol; Timothy Wilkin; Mary Young; Mardge Cohen; Howard Minkoff; Stephen J Gange; Ruth M Greenblatt Journal: AIDS Date: 2006-04-24 Impact factor: 4.177
Authors: Anuradha Rebbapragada; Charles Wachihi; Christopher Pettengell; Sherzana Sunderji; Sanja Huibner; Walter Jaoko; Blake Ball; Keith Fowke; Tony Mazzulli; Francis A Plummer; Rupert Kaul Journal: AIDS Date: 2007-03-12 Impact factor: 4.177
Authors: Connie Celum; Anna Wald; James Hughes; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Martin Casapia; Abner Ortiz; Jonathan Fuchs; Susan Buchbinder; Beryl Koblin; Sheryl Zwerski; Scott Rose; Jing Wang; Lawrence Corey Journal: Lancet Date: 2008-06-21 Impact factor: 79.321
Authors: Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Deborah Watson-Jones; Helen A Weiss; Mary Rusizoka; John Changalucha; Kathy Baisley; Kokugonza Mugeye; Clare Tanton; David Ross; Dean Everett; Tim Clayton; Rebecca Balira; Louise Knight; Ian Hambleton; Jerome Le Goff; Laurent Belec; Richard Hayes Journal: N Engl J Med Date: 2008-03-12 Impact factor: 91.245
Authors: Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Tae Joon Yi; Brett Shannon; Rupert Kaul; W Conrad Liles; Sharon L Walmsley Journal: AIDS Res Hum Retroviruses Date: 2014-12-17 Impact factor: 2.205
Authors: Sara Gianella; Andrew D Redd; Mary K Grabowski; Aaron A R Tobian; David Serwadda; Kevin Newell; Eshan U Patel; Sarah Kalibbala; Paschal Ssebbowa; Ronald H Gray; Thomas C Quinn; Steven J Reynolds Journal: J Infect Dis Date: 2015-03-05 Impact factor: 5.226
Authors: Jennifer A Slyker; Barbra Richardson; Michael H Chung; Claire Atkinson; Kristjana H Ásbjörnsdóttir; Dara A Lehman; Michael Boeckh; Vincent Emery; James Kiarie; Grace John-Stewart Journal: AIDS Res Hum Retroviruses Date: 2016-12-06 Impact factor: 2.205
Authors: Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald Journal: AIDS Date: 2018-11-13 Impact factor: 4.177
Authors: Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull Journal: J Virol Date: 2020-12-09 Impact factor: 5.103
Authors: Kenneth H Fife; Kenneth Mugwanya; Katherine K Thomas; Jared M Baeten; Connie Celum; Elizabeth Bukusi; Guy de Bruyn; Andrew Mujugira; Bellington Vwalika; Anna Wald; Jairam R Lingappa Journal: J Infect Dis Date: 2015-12-23 Impact factor: 5.226